<?xml version="1.0" encoding="UTF-8"?>
<collection xmlns="http://www.loc.gov/MARC21/slim">
 <record>
  <leader>     caa a22        4500</leader>
  <controlfield tag="001">477061591</controlfield>
  <controlfield tag="003">CHVBK</controlfield>
  <controlfield tag="005">20180405111402.0</controlfield>
  <controlfield tag="007">cr unu---uuuuu</controlfield>
  <controlfield tag="008">170330e19960301xx      s     000 0 eng  </controlfield>
  <datafield tag="024" ind1="7" ind2="0">
   <subfield code="a">10.1007/BF01061916</subfield>
   <subfield code="2">doi</subfield>
  </datafield>
  <datafield tag="035" ind1=" " ind2=" ">
   <subfield code="a">(NATIONALLICENCE)springer-10.1007/BF01061916</subfield>
  </datafield>
  <datafield tag="100" ind1="1" ind2=" ">
   <subfield code="a">Hughes</subfield>
   <subfield code="D">Robert</subfield>
   <subfield code="u">Harvard Medical School and Antithrontbotic Therapy Unit, Massachusetts General Hospital, Boston, Massachusetts</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="245" ind1="1" ind2="0">
   <subfield code="a">Workshop: Reimbursement for anticoagulation services</subfield>
   <subfield code="h">[Elektronische Daten]</subfield>
   <subfield code="c">[Robert Hughes]</subfield>
  </datafield>
  <datafield tag="520" ind1="3" ind2=" ">
   <subfield code="a">Anticoagulant therapy units (ATUs) have been developed to enhance quality expertise in the care of patients receiving anticoagulant therapy with warfarin and to coordinate care. The Anticoagulation Forum, representing the program directors and staff of ATUs, surveyed its membership for its 1995 National Conference on Anticoagulation Therapy. Responses were received from 109 programs with an average of 467 patients each. The consensus of program directors was that inadequate reimbursement was an important deterrent to the expansion of such care. A review of current literature reveals substantially superior outcomes in anticoagulation units versus routine care, with estimates of 4.5 fewer major bleeding events per 100 patient-years of treatment and 6 fewer thromboembolic events per 100 patientyears of treatment. The Anticoagulation Forum encourages third-party payers to develop appropriate strategies to reimburse this type of care, which should substantially improve the outcomes of anticoagulant therapy while reducing overall costs.</subfield>
  </datafield>
  <datafield tag="540" ind1=" " ind2=" ">
   <subfield code="a">Kluwer Academic Publishers, 1996</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">anticoagulant therapy</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">warfarin</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">reimbursement</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">cost effectiveness</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="773" ind1="0" ind2=" ">
   <subfield code="t">Journal of Thrombosis and Thrombolysis</subfield>
   <subfield code="d">Kluwer Academic Publishers</subfield>
   <subfield code="g">2/4(1996-03-01), 301-304</subfield>
   <subfield code="x">0929-5305</subfield>
   <subfield code="q">2:4&lt;301</subfield>
   <subfield code="1">1996</subfield>
   <subfield code="2">2</subfield>
   <subfield code="o">11239</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2="0">
   <subfield code="u">https://doi.org/10.1007/BF01061916</subfield>
   <subfield code="q">text/html</subfield>
   <subfield code="z">Onlinezugriff via DOI</subfield>
  </datafield>
  <datafield tag="908" ind1=" " ind2=" ">
   <subfield code="D">1</subfield>
   <subfield code="a">research-article</subfield>
   <subfield code="2">jats</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">856</subfield>
   <subfield code="E">40</subfield>
   <subfield code="u">https://doi.org/10.1007/BF01061916</subfield>
   <subfield code="q">text/html</subfield>
   <subfield code="z">Onlinezugriff via DOI</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">100</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Hughes</subfield>
   <subfield code="D">Robert</subfield>
   <subfield code="u">Harvard Medical School and Antithrontbotic Therapy Unit, Massachusetts General Hospital, Boston, Massachusetts</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">773</subfield>
   <subfield code="E">0-</subfield>
   <subfield code="t">Journal of Thrombosis and Thrombolysis</subfield>
   <subfield code="d">Kluwer Academic Publishers</subfield>
   <subfield code="g">2/4(1996-03-01), 301-304</subfield>
   <subfield code="x">0929-5305</subfield>
   <subfield code="q">2:4&lt;301</subfield>
   <subfield code="1">1996</subfield>
   <subfield code="2">2</subfield>
   <subfield code="o">11239</subfield>
  </datafield>
  <datafield tag="900" ind1=" " ind2="7">
   <subfield code="a">Metadata rights reserved</subfield>
   <subfield code="b">Springer special CC-BY-NC licence</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="898" ind1=" " ind2=" ">
   <subfield code="a">BK010053</subfield>
   <subfield code="b">XK010053</subfield>
   <subfield code="c">XK010000</subfield>
  </datafield>
  <datafield tag="949" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="F">NATIONALLICENCE</subfield>
   <subfield code="b">NL-springer</subfield>
  </datafield>
 </record>
</collection>
